Cosmo Pharmaceuticals (OTC:CMOPF) Coverage Initiated by Analysts at Credit Suisse Group

Research analysts at Credit Suisse Group began coverage on shares of Cosmo Pharmaceuticals (OTC:CMOPFGet Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage set an “outperform” rating and a CHF 64 price target on the stock.

Shares of CMOPF stock opened at 47.50 on Thursday. Cosmo Pharmaceuticals has a fifty-two week low of 47.50 and a fifty-two week high of 74.00.

Cosmo Pharmaceuticals Company Profile (Get Rating)

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy.

Featured Stories

The Fly logo

Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.